Back to Noidecs or All Bud/Flower

Details provided are based upon best-known information made available to MedBud, please reconfirm with your pharmacy. This page was last updated:
MedBud typically only updates products when availability changes, or new information is provided. An availability status from several months ago can still be valid when a product remains in/out of stock, or has been discontinued.

Terpene Profile (Strain Estimate)

Alpha-PineneMajorPine/Sharp156℃
MyrceneMajorHerbal/Musk166-168℃
LimoneneMajorCitrus/Sour177℃
LinaloolMajorFloral/Lavender198℃

MedBud currently tracks 16 common terpenes, 22 more pending addition.

No full terpene profile has been provided for this product, information above may be estimated based on public strain information.

Dosing Look-Up Table (Estimated)

0.01/g2.2/mg THCTrace CBD
0.05/g11/mg THCTrace CBD
0.1/g22/mg THCTrace CBD
0.15/g33/mg THCTrace CBD
0.2/g44/mg THCTrace CBD
0.25/g55/mg THCTrace CBD
0.3/g66/mg THCTrace CBD
/gCalculate THCCalculate CBD

Please note values above are based on registered THC/CBD percentages, subject to ±10% allowed variance. Values provided are 'best case', losses to air during vaporisation or combustion will always occur.

Medication Details

Brand
United Kingdom Noidecs
Designation
T22
Cultivar/Strain
Sensi Star
Classification
Indica Hybrid
Chemotype
Type I: High THC
Flower Provided
Trimmed Whole Flower
THC Potential Range (±10%)
19.8-24.2%
CBD Potential Range (±10%)
<1%
Cultivated/Produced by
Portugal GroVida
Cultivated or Packaged in
Flag of Portugal Portugal
Irradiation
Gamma-Irradiated
Monograph Conformity
5.1.4
Imported by
United Kingdom Eaststone
Imported as
Schedule II: Finished Product

Stock Availability

We provide stock/pharmacy information only for use by medical cannabis patients, clinicians and pharmacists*.

Best-Known Status: Available

We try to ascertain stock status strictly based on the importer/distributor supplying pharmacies. Availability at individual pharmacies will differ.

*Cannabis is a controlled-substance and can only be legally dispensed upon submission of a valid prescription from a prescribing clinic, ordinarily listed.

Dispensing Patient Pharmacies

Product Description Video Reviews0 Patient Reviews

About Sensi Star

SnSIndica Hybrid

High Times Cannabis Cup winner for 1999, 2000 and 2005. Highlife Cup Hydro winner in 2009 and 2010.

Paradise Seeds Logo

Bred by Dutch Flag Paradise Seeds

Sensi Star is an award-winning indica dominant hybrid. Sensi Star was created by the crew at Paradise Seeds and they have not released the full truth of this strain's genetics. They have stated that it is mostly an Afghani indica but the strain most definitely contains some sativa, possibly Skunk, in her lineage (we estimate it at 35 percent).

The nuggets develop into dark, dark green cones that are covered with trichomes. They develop clusters of long, orange hairs. Sensi Star smells of a coniferous forest, mint, pepper, and a citrus lemon; which is similar to the taste of the strain.

Growing well in the Sea of Green technique, Sensi Star flowers for about seven weeks. Indoor this strain can yield up to 450 grams per plant, though reportedly it can produce up to three and a half pounds when grown properly. It does well when grown with a hydroponics setup. Sensi Star usually tops out at a height of six feet.

Description provided by Wikileaf.

Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).

United Kingdom About Lyphe Group Ltd

Noidecs Logo

From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.

At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.

lyphegroup.com

  Information provided is partially community sourced and may be outdated or otherwise incorrect. Please report any inaccuracies found by email.

NHS LogoFurther National Health-Service Information on Cannabis-Based Products for Medicinal Use (CBPMs)